Progyny, Inc. $PGNY Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL trimmed its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 46.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 250,849 shares of the company’s stock after selling 221,184 shares during the period. Tudor Investment Corp ET AL’s holdings in Progyny were worth $5,398,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Federated Hermes Inc. grew its holdings in Progyny by 147.3% during the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after acquiring an additional 819 shares during the period. Versant Capital Management Inc grew its holdings in Progyny by 61.8% during the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after acquiring an additional 894 shares during the period. Covestor Ltd grew its holdings in Progyny by 164.9% in the third quarter. Covestor Ltd now owns 2,609 shares of the company’s stock valued at $56,000 after purchasing an additional 1,624 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Progyny in the second quarter valued at approximately $77,000. Finally, Quarry LP grew its holdings in Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Wall Street Zen lowered Progyny from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. BTIG Research dropped their price objective on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Barclays dropped their price objective on Progyny from $29.00 to $23.00 and set an “overweight” rating on the stock in a report on Friday, March 20th. Citigroup raised Progyny to an “outperform” rating in a report on Tuesday, January 20th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Friday, March 27th. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $27.91.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the transaction, the executive vice president owned 89,879 shares in the company, valued at $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 7,455 shares of company stock valued at $129,515 in the last quarter. Company insiders own 9.40% of the company’s stock.

Progyny Price Performance

NASDAQ PGNY opened at $16.93 on Thursday. The company has a market cap of $1.33 billion, a PE ratio of 26.05, a price-to-earnings-growth ratio of 0.96 and a beta of 0.99. The stock’s 50 day simple moving average is $19.32 and its 200-day simple moving average is $22.06. Progyny, Inc. has a 1-year low of $16.28 and a 1-year high of $28.75.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, equities research analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.